Charles River Laboratories International, Inc.

Based on a comprehensive assessment of CRL, the analysis yields a cautious 'Hold' recommendation, with significant risks currently outweighing the potential for reward.

Technical Outlook: The stock is in a volatile downtrend with a severe recent drop, indicating negative momentum. While it has outperformed over three months, the high beta suggests continued instability, making timing an entry difficult. Fundamental Health: CRL's fundamentals are a major concern. The swing to a deep net loss and weak cash flow raise red flags about near-term profitability and financial flexibility, overshadowing a stable core EBITDA. Valuation & Risk: The negative P/E ratios reflect the lack of current earnings. While the low PEG ratio hints at deep value if future growth is achieved, this is a highly speculative bet given the high EV/EBITDA and substantial volatility risk.

Recommendation: Hold. CRL presents a high-risk, potentially high-reward scenario that is unsuitable for most investors. The current combination of poor profitability, weak liquidity, and extreme price volatility suggests it is not worth buying at this time. Investors should wait for clear signs of a fundamental turnaround and price stabilization before considering a position.

RockFlow Model Forecast: Three Scenarios for 2026

Based on a comprehensive analysis, the 12-month outlook for CRL is highly cautious. The primary catalyst for any upside would be a successful execution of a turnaround plan that returns the company to profitability and improves its weak cash flow. However, significant risks dominate the outlook, including the persistent net losses, financial instability implied by the negative P/E, and the stock's high volatility. Given the severe downtrend and lack of a clear positive catalyst, investors should maintain a Hold stance, with a price expectation likely to remain volatile within a wide range, potentially between $140 and $190, until fundamental improvements materialize.

Wall Street Consensus

Most Wall Street analysts are optimistic about Charles River Laboratories International, Inc.'s 12-month outlook, with consensus target around $178.49, indicating expected upside potential.

Overall, CRL has investment potential but also faces challenges. Here are key factors to weigh before investing.

CRL has demonstrated extreme volatility over the past year, experiencing a significant drawdown despite a recent quarterly gain.

The stock has suffered a severe short-term decline of over 20% in the past month; however, it still holds a positive 8.26% return over three months, modestly outperforming the market by 2.63%. This recent sharp selloff suggests a notable shift in sentiment or reaction to new information.

Currently trading at $175.46, CRL is positioned approximately in the upper-middle portion of its 52-week range, below the midpoint but well above its low. Despite the recent drop, the substantial volatility indicated by its high beta suggests the price could remain susceptible to large swings, warranting caution regarding immediate directional bias.

Revenue & Profitability: Revenue declined slightly to $994 million in Q4 from $1.0 billion in Q3, though the core operating performance remained stable with an EBITDA ratio near 20%. However, the quarter was severely impacted by significant non-operating expenses, leading to a substantial net loss of $277 million and a deeply negative net profit margin of -27.8%, a stark reversal from the profitability achieved in the prior quarter.

Financial Health: The company maintains a moderate debt load with a debt-to-equity ratio of 0.97, but liquidity is a concern with a low cash ratio of 0.19. The cash flow to debt ratio is weak at 0.05, indicating limited capacity to service obligations from operating cash flows, which is a significant risk factor despite an acceptable interest coverage ratio of 5.1.

Operational Efficiency: Operational metrics are mixed, with a negative Return on Equity (-8.7%) reflecting the quarterly loss, while Return on Capital Employed remained positive but low at 2.0%. Asset utilization is poor, as evidenced by a low asset turnover of 0.14, suggesting significant capital is not being efficiently deployed to generate sales.

Based on the negative trailing PE ratio (-115.43), CRL is currently unprofitable on a GAAP basis, making the TTM valuation metric uninformative. While the forward PE ratio remains negative (-9.06), suggesting profitability is not expected in the near term, the exceptionally low PEG ratio of 0.015 implies that if earnings growth materializes as forecasted, the stock appears significantly undervalued based on its growth prospects. However, the high EV/EBITDA of 64.86 confirms that cash flow metrics also indicate a premium valuation.

A peer comparison cannot be conducted as industry average data is not available. The absence of benchmark data makes it impossible to determine how CRL's P/B ratio of 2.72 and EV/EBITDA of 64.86 compare to its sector, leaving the valuation assessment incomplete without a relative context. Therefore, the analysis is limited to an absolute perspective based solely on the company's own metrics.

Volatility Risk: CRL's beta of 1.62 indicates it is significantly more volatile than the broader market, amplifying potential swings in both directions. This elevated volatility is confirmed by a substantial one-year maximum drawdown of -43.62%, highlighting a pronounced downside risk and potential for severe capital depreciation during market downturns.

Other Risks: While the absence of notable short interest suggests the market lacks strong negative sentiment or a targeted bearish thesis, investors should be aware of other factors such as stock-specific liquidity and company fundamentals which still carry inherent risks. The lack of short interest does not preclude the possibility of declines driven by earnings misses, sector-specific headwinds, or broader economic conditions.